Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The company delivered a Q3 revenue miss and large guide-down, ...
CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results